ASCO A Focus On Leukemia eBook
ASCO Leukemia 2022.indd
eBook (Meeting Coverage)
CMSC: A Focus On MS eBook
CMSC ON MS Conference Report.indd
AAN 2022 eBOOK: A Focus on Multiple Sclerosis
AAN 2022 MS Neurov1.indd
ACTRIMS eBook
Focus on MS MAY 2022v2.indd
SGO eBook
SGO Gynecologic Cancer 2022
ASCO GU eBook
ASCO Genitourinary Cancer Renal 2022.indd
ASH 2021: A Focus on Leukemia & Lymphoma
Focus on Lymphoma Leukemia
Patients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs
According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...
Venetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL
The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...
Delayed Start of Therapy Feasible in Some Patients With MCL
Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...
Addition of Ibrutinib to Chemoimmunotherapy in CLL
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...
